Melanoma Institute Australia joins forces with Wollongong Wolves in the fight against melanoma
6 February 2017
The world’s largest melanoma-specific treatment and research facility, Melanoma Institute Australia, is joining forces with the Wollongong Wolves Football Club in the battle to reduce Australia’s melanoma rates.
CEO of Melanoma Institute Australia, Carole Renouf, announced the partnership at a function in Wollongong in support of Wolves’ legend David Cervinski who is battling melanoma.
Ms Renouf said the partnership between MIA and the Wollongong Wolves would help promote sun safe behaviour amongst Wolves’ players and also spread the life-saving message to family and fans.
“It is crucial that young Australians take steps now to protect their skin from sun damage,” Ms Renouf said. “Intense, intermittent sun exposure leading to sunburn, especially before puberty, significantly increases your risk of developing melanoma in the future.
“The real tragedy of melanoma is that it is largely preventable, so we are delighted to be working with the Wollongong Wolves from the grass roots level to change behaviour and save lives.”
CEO of Wollongong Wolves Football Club Chris Papakosmas said, “Partnering with Melanoma Institute Australia is one of the most important sponsorships for our club. Following on from David Cervinski’s recent battles we thought this was a great way to raise awareness.”
One Australian dies from melanoma every six hours. Melanoma is the most common cancer affecting 15-39 year-old Australians and the leading cause of cancer death in 20-39 year-olds. The incidence of melanoma in the over 60s is also high, a legacy of sun-damage from decades ago.
As part of the partnership, Melanoma Institute Australia’s logo will feature prominently on the 2017 jerseys of all Wollongong Wolves juniors. There will also be ongoing education, sun-safety and fundraising campaigns, including the Wolves involvement in MIA’s annual Melanoma March fundraising event at Wollongong’s Stuart Park on Sunday 12 March.
“This partnership is crucial in tackling melanoma head on,” said Ms Renouf. “We are delighted to be working with the Wollongong Wolves and together help end melanoma for future generations.”
Wolves’ fans can join the fight against melanoma by participating in Melanoma March Wollongong on Sunday 12 March. To register, go to www.melanomamarch.org.au
Australian melanoma clinical practice guidelines have been published on a wiki platform for the first time as researchers try to keep up to date with emerging evidence.
Carole Renouf, CEO of Melanoma Institute Australia is asking young Australians who have been affected by melanoma to share their experiences with her.
Melanoma Institute Australia CEO Carole Renouf wants to make sure Aussies remember to take care of our skin as the festive season draws closer and we spend more time in the sun.
Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.
We have developed a unique clinical trial that will use existing drugs to target rare genes in melanoma patients.
Data presented at the recent ASCO Annual Meeting showcased advances in melanoma research, particularly long-term survival data.